Pulmonary artery hypertension: Caveolin-1 and eNOS interrelationship: A new perspective

Cardiology in Review

Volumn 15, Issue 3, 2007, Pages 143-149

  Mathew, Rajamma ^a,b   Huang, Jing ^a   Gewitz, Michael H ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Caveolin 1; eNOS; Pulmonary artery hypertension; STAT3

Indexed keywords

ARGININE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; STAT3 PROTEIN;

BIOAVAILABILITY; CAVEOLA; CELL MEMBRANE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; HUMAN; HYPOXIA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CAVEOLIN 1; CELL MEMBRANE; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VASCULAR RESISTANCE;

EID: 34247232180     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000249381.49138.b9     Document Type: Review

References (113)

1. Mathew R, Gewitz MH. Pulmonary hypertension in infancy and childhood. Heart Dis. 2000;2:362-368.
2. Murphy JD, Rabinovitch M, Goldstein JD, et al. The structural basis of persistent pulmonary hypertension. J Pediatr. 1981;98:962-967.
3. Mourani PM, Ivy DD, Gao D, et al. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004;170:1006-1013.
4. Meyrick B, Perkett EA, Brigham KL. Inflammation and models of pulmonary hypertension. Am Rev Respir Dis. 1987;136:765-767.
5. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
6. Palevski HI, Shloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure and responsiveness to vasodilator agents. Circulation. 1989;80:1207-1221.
7. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006;3:111-115.
8. Vane JR, Angaard EE, Botting RM. Regulatory function of the vascular endothelium. N Engl J Med. 1990;323:27-36.
9. Rich S, Brundage BH. Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol. 1989;14:545-550.
10. Steinhorn RH, Russel JA, Lakshminrusimha S, et al. Altered endothelium dependent relaxation in lambs with high pulmonary blood flow and pulmonary hypertension. Am J Physiol. 2001;280:H311-H317.
11. Adnot S, Raffestin B, Addahibi S, et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155-162.
12. Mathew R, Zeballos GA, Tun H, et al. Role of nitric oxide and endothelin-1 in monocrotaline-induced PH in rats. Cardiovasc Res. 1995;30:739-746.
13. Dinh-Xuan AT, Pepke-Zaba J, Butt AY, Cremona G, Higenbottam TW. Impairment of pulmonary artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to endothelial cell membrane receptors nor to l-arginine deficiency. Br J Pharmacol. 1993;109:587-591.
14. Dinh-Xuan AT, Higenbottam TW, Clelland C, et al. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger syndrome. Br J Pharmacol. 1990;99:9-10.
15. Celermajer DS, Cullen S, Deanfield JE. Impairment of endotheliumdependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:4409-446.
16. Mathew R, Fan NY-T, Yuan N, et al. Inhibition of nitric oxide synthase enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats. Am J Physiol. 2000;278:L81-L89.
17. Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: randomized double-blind study. Lancet. 2000;356:1464-1469.
18. Roberts JJR, Roberts CT, Jones RC, et al. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res. 1995;76:215-222.
19. Mathew R, Gloster ES, Rajan TS, et al. Role of inhibition of nitric oxide in monocrotaline-induced pulmonary hypertension in rats. Am J Physiol. 1997;82:1493-1498.
20. Kourembanas S, McQuillan LP, Leung GK, et al. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92:99-104.
21. Ignarro LJ, Buga GM, Wei LH, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci. 2001;98:4202-4208.
22. Scott-Burden T, Vanhoutte PM. The endothelium is a regulator of vascular smooth muscle proliferation. Circulation. 1993;87(Suppl V):V51-V55.
23. Cooke JP. NO and angiogenesis. Atherosclerosis (Suppl). 2003;4:53- 60.
24. Ni C-W, Hsieh H-J, Chao Y-J, et al. Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow. Am J Physiol. 2004;287:C771-C780
25. Peng HB, Libby P, Liao JK. Induction and stabilization of Iκ Bα by NO mediates inhibition of NF-κ B. J Biol Chem. 1995;270:14214-14219.
26. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci. 1991;88:4651-4655.
27. Radomski MW, Palmer RM, Moncada S. Modulation of platelet aggregation by an l-arginine-nitric oxide pathway. Trends Pharmacol Sci. 1991;12:87-88.
28. Chae IH, Park K-W, Kim H-S, et al. Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression, transition of cytochrome c, and activation of caspase-3 in rat vascular smooth muscle cells. Clin Chim Acta. 2004;341:83-91.
29. Tomita H, Egashira K, Kubo-Inoue M, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol. 1998;18:1456-1464.
30. Moncada S, Palmar RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-143.
31. Ignaro LJ, Buga GM, Woods SS, et al. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci. 1987;84:9265-9269.
32. Forstermann U, Close EI, Pollock JS, et al. Nitric oxide synthase isoenzymes characterization, purification, molecular cloning and function. Hypertension. 1994;23:1121-1131.
33. Fagan KA, Fouty BW, Tyler RC, et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest. 1999;103:291-299.
34. Han RN, Stewart DJ. Defective lung vascular development in endothelial nitric oxide synthase deficient mice. Trends cardiovasc Med. 2006;16:29-34.
35. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
36. Mason NA, Springall DR, Burke M, et al. High expression of endothelial synthase in plexiform lesions of pulmonary hypertension. J Pathol. 1998;185:313-318.
37. Fulton D, Fontana J, Sowa G, et al. Localization of endothelial nitric oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J Biol Chem. 2002;277:4277-4284.
38. Michel T, Feron O. Nitric oxide synthases: which, where, how and why? J Clin Invest. 1997;100:2146-2152.
39. Kone BC. Protein-protein interaction controlling nitric oxide synthase. Acta Physiol Scand. 2000;168:27-31.
40. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
41. Fulton D, Gratton J-P, McCabe TJ, et al. Regulation of endotheliumderived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
42. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Ann Rev Physiol. 2002;64:749-774.
43. Shaul PW, Smart EJ, Robinson LJ, et al. Acylation targets endothelial nitric oxide synthase to plasmalemmal caveolae. J Biol Chem. 1998;271:6518-6522.
44. Anderson RG. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci. 1993;90:1090-10913.
45. Gratton J-P, Fontana J, O'Connor DS, et al. Reconstitution of an endothelial nitric oxide synthase (eNOS), hsp90 and Caveolin-1 complex in vitro. J Biol Chem. 2000;275:22268-22277.
46. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001;276:32663-32669.
47. McDonald KK, Zharikov S, Block ER, et al. A caveolar complex between cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the "arginine paradox". J Biol Chem. 1997;272:31213-31216.
48. 2+-calmodulin and caveolin. J Biol Chem. 1997;272:15583-15586.
49. 2+-dependent signal transduction. Traffic. 2003;4:717-723.
50. + channels in vascular endothelium. J Biol Chem. 2005;280:11564-11565.
51. Linder AE, McCluskey LP, Cole KR, et al. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther. 2005;314:9-15.
52. Ju H, Venema VJ, Liang H, et al. Bradykinin activates the janusactivated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signaling proteins in plasmalemmal caveolae. Biochem J. 2000;351:257-264.
53. Lebrecque L, Royal I, Surprenant DS, et al. Regulation of vascular endothelial growth factor receptor 2 activity by caveolin-1 and plasmalemmal membrane cholesterol. Mol Biol Cell. 2003;14:334-347.
54. Williams TM, Lisanti MP. The caveolin genes: from biology to medicine. Ann Med. 2004;36:584-595.
55. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998;273:54119-54122.
56. Simons K, Toomre D. Lipid rafts and signal transduction. Nature Rev Mol Cell Biol. 2000;1:31-39.
57. Quest AF, Leyton L, Párraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling and disease. Biochem Cell Biol. 2004;82:129-144.
58. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 1999;19:7289-7304.
59. Kogo H, Fujimoto. Caveolin-1 isoforms are encoded by distinct mRNAs. Identification of mouse caveolin-1 mRNA variants caused by alternative transcription initiation and splicing. FEBS Lett. 2000;465:119-123.
60. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase. Why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
61. Feron O, Saldana F, Michel JB, et al. The endothelial nitric oxide synthase-caveolin regulation cycle. J Biol Chem. 1998;273:3125-3128.
62. Yu J, Bergaya S, Murata T, et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest. 2006;116:1284-1291.
63. Sonveaux P, Martinive P, DeWever J, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res. 2004;95:154-161.
64. Liu J, Razani B, Tang S, et al. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells: angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem. 1999;274:15781-15785.
65. Griffoni C, Spisni E, Santi S, et al. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 2000;276:756-761.
66. Liu J, Wang XB, Park DS, et al. Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem. 2002;277:10661- 10668.
67. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121-28138.
68. Park DS, Cohen AW, Frank PG, et al. Caveolin-1 null (-/-) mice show dramatic reduction in the life span. Biochemistry. 2003;42:15124-15131.
69. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449-2452.
70. Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci. 2002;99:11375-11380.
71. Liu J, Lee P, Galbiati F, et al. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol. 2001;280:C823-C835.
72. Hassan GS, Williams TM, Frank PG, et al. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction. Am J Physiol. 2006;290:H2393-H2401.
73. Hassan GS, Jasmin JF, Schubert W, et al. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry. 2004;43:8312-8321.
74. Peterson TE, Guicciardi ME, Gulati R, et al. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterial Thromb Vasc Biol. 2003;23:1521-1527.
75. Galbiati F, Volonte D, Engelman JA, et al. Targeted downregulation of caveolin-1 is sufficient to drive all transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 1998;17:6633-6648.
76. Engelman JA, Wykeff CC, Yasuhara S, et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-dependent growth. J Biol Chem. 1997;272:16374-16381.
77. Gargalovic P, Dory L. Cellular apoptosis is associated with increased caveolin-1 expression in macrophages. J Lipid Res. 2003;44:1622-1633.
78. WAF1/cip1-dependent mechanism. Mol Biol Cell. 2001;12:2229-2244.
79. Kim HP, Wang X, Nakao A, et al. Caveolin-1 expression by means of p38β mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci. 2005;102:11319-11324.
80. Garaci MW, Moore M, Gesell T, et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension, a gene array microanalysis. Circ Res. 2001;88:555-562.
81. Mathew R, Huang J, Shah M, et al. Disruption of endothelial cell caveolin-1α/raft scaffolding during development of monocrotalineinduced PH. Circulation. 2004;110:1499-1506.
82. Jasmin JF, Mercier I, Hnasko R, et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res. 2004;63:747-755.
83. Achcar RD, Demura Y, Rai PR, et al. Loss of caveolin-1 and hemoxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
84. Jasmin JF, Mercier I, Sotgia F, et al. SOCS preotins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol Metabol. 2006;17:150-158.
85. Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1-24.
86. Darnell JE Jr. STATs and gene regulation. Science. 1997;272:1630-1645.
87. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Natl Acad Sci. 1997;94:3801-3804.
88. Gritsko T, Williams A, Turkson J, et al. Persistent activation of STAT3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11-19.
89. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. STAT3 as an oncogene. Cell. 1999;98:295-303.
90. Bienvenu F, Barré B, Giraud S, et al. Transcriptional regulation by a DNA-associated form of cyclin D1. Mol Biol Cell. 2005;16:1850-1858.
91. Kanno S, Wu YJ, Lee PC, et al. Angiotensin converting enzyme inhibitor preserves p21 and eNOS expression in MCT-induced PH in rats. Circulation. 2001;104:945-950.
92. Conte MS, Altieri DC. Survivin regulation of vascular injury. Trends Cardiovasc Med. 2006;16:114-117.
93. McMurtry MS, Archer SI, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary hypertension. J Clin Invest. 2005;115:1479-1491.
94. Blanc-Brude OP, Yu J, Simosa H, et al. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med. 2002;8:987-994.
95. Gao LF, Wen LJ, Yu H, et al. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin. 2006;27:347-352.
96. Shibata R, Kai H, Seki Y, et al. Inhibition of STAT3 prevents neointimal formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum Gene Ther. 2003;14:601-610.
97. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol. 2005;288:C494-C506.
98. Hodge DR, Hurt EM, Ferrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-2512.
99. Torres VA, Tapia JC, Rodriguez DA, et al. Caveolin-1 controls cell proliferation and cell death by suppressing expression of apoptosis protein survivin. Cell Sci. 2006;119:1812-1823.
100. Hulit J, Bash T, Fu M, et al. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem. 2000;275:21203-21209.
101. Tuder RM, Groves B, Badesch DM, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesion of pulmonary hypertension. Am J Pathol. 1994;144:275-295.
102. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628 -1631.
103. Bhargava A, Kumar A, Yuan N, et al. MCT induces interleukin-6 mRNA expression in rat lungs. Heart Dis. 1999;1:126-132.
104. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95-98.
105. Mathew R, Huang J, Gewitz M. Monocrotaline disrupts caveolae-based signaling molecules contributing to impaired eNOS. FASEB. 2005: Abstract A1011.
106. waf1/cip1 in the regulation of vascular smooth muscle proliferation by nitric oxide. Proc Natl Acad Sci. 2001;98:12802-12807.
107. Wang X-M, Kin H-P, Song R, et al. Caveolin-1 confers anti-inflammatory effects in murine macrophages via the MK3/p38 MAPK pathway. Am J Respir Cell Mol Biol. 2006;34:434-442.
108. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci. 2001;98:3583-3588.
109. Chao J-I, Kuo P-C, Hsu T-S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004;279:20267-20276.
110. Resta TC, Gonzales RJ, Dail WG, et al. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol. 1997;272:H806-H813.
111. Xue C, John RA. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxia rat. Hypertension. 1996;28:743-753.
112. Ozaki M, Kawashima S, Yamashita T, et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension. 2001;37:322-327.
113. Murata T, Sato K, Hori M, et al. Decreased endothelial nitric oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced PH. J Biol Chem. 2002;277:44085-44092.